YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
The retinitis pigmentosa market is expected to witness steady growth over the coming years, supported by increasing awareness of inherited retinal disorders, advances in genetic testing, and the development of disease-modifying therapies.…
Healthcare stocks edged higher Friday afternoon, with the NYSE Healthcare Index and the State Street PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
[Red dollar sign pointing down with arrow, concept of financial loss, market decline and recession, 3d render] Ocugen (OCGN [https://seekingalpha.com/symbol/OCGN]) fell nearly 14% on Wednesday to record its worst single-day decline since M…
Ocugen OCGN announced that it has dosed the first patient in the global phase III ArMaDa3 study evaluating the modifier gene therapy candidate, OCU410, for treating geographic atrophy ("GA") secondary to dry age-related macular degeneratio…
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chairman, Chief Executive Officer, and Co-Founder - Shankar MusunuriChief Financial Officer - Rita Johnson-GreeneExecutive Vice President of Comme…
Ocugen OCGN reported a second-quarter 2026 loss of 7 cents per share, which was wider than the Zacks Consensus Estimate as well as the year-ago loss of 5 cents. Higher research and development spending weighed on results. Revenues rose 8.4…
* Ocugen (OCGN [https://seekingalpha.com/symbol/OCGN]) is scheduled to announce Q2 earnings results on Thursday, August 6th, before market open. * The consensus EPS Estimate is -$0.05 [https://seekingalpha.com/symbol/OCGN/earnings/estimate…
MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovativ…
Illumina (ILMN) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.19 per share a year ago. These figures are adjusted for non-recurring items. This…
(RTTNews) - Ocugen, Inc. (OCGN), a biotechnology company developing gene therapies for blinding diseases, announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) status to OCU410 for the treatment of Geographi…
Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400 MALVERN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocu…
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovativ…
Is EWTX a good stock to buy? We came across a bullish thesis on Edgewise Therapeutics, Inc. on BioEquity Watch's Substack. In this article, we will summarize the bulls' thesis on EWTX. Edgewise Therapeutics, Inc.'s share was trading at $38…
Is ABSI a good stock to buy? We came across a bullish thesis on Absci Corporation on TradersPro's Substack. In this article, we will summarize the bulls' thesis on ABSI. Absci Corporation's share was trading at $7.27 as of June 15th.Ocugen…
Is MANE a good stock to buy? We came across a bullish thesis on Veradermics, Incorporated on TradersPro's Substack. In this article, we will summarize the bulls' thesis on MANE. Veradermics, Incorporated's share was trading at $90.95 as of…
Is RAPP a good stock to buy? We came across a bullish thesis on Rapport Therapeutics, Inc. on TradersPro's Substack. In this article, we will summarize the bulls' thesis on RAPP. Rapport Therapeutics, Inc.'s share was trading at $38.26 as…
Is BNTX a good stock to buy? We came across a bullish thesis on BioNTech SE on r/ValueInvesting by birdflustocks. In this article, we will summarize the bulls' thesis on BNTX. BioNTech SE's share was trading at $86.50 as of June 9th. BNTX'…
Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.'s share was trading at $…
A month has gone by since the last earnings report for Ocugen (OCGN). Shares have lost about 10.7% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to i…
Ocugen OCGN is advancing a retinal pipeline built around durability and breadth. Its focus is a modifier gene therapy platform aimed at inherited retinal diseases and blindness conditions, using one-time subretinal dosing intended to reach…
Ocugen OCGN is pushing three eye gene therapy programs toward late-stage regulatory timelines, setting up a catalyst-heavy stretch in 2026 and 2027. That opportunity comes with familiar biotech trade-offs. The company has no approved produ…
Ocugen OCGN is advancing one-time subretinal gene therapies for inherited retinal diseases where patients face large unmet need and limited treatment options. With three lead ocular programs moving through mid- and late-stage development o…
[Health Care sector, stock exchange monitor with index information.] Torsten Asmus The semi-annual rebalancing of U.S. equities is officially underway after FTSE Russell unveiled its preliminary list of shifts for the broad-market Russell…
Ocugen OCGN incurred a loss of 6 cents per share in the first quarter of 2026, wider than the Zacks Consensus Estimate as well as the year-ago loss of 5 cents. Ocugen’s total revenues rose 3.5% year over year to $1.5 million in the first q…
Ocugen logo Key Points Ocugen announced a $115 million offering of convertible senior notes expected to close May 7, 2026, which the company says will leave it with about $112.1 million in cash equivalents at closing (or ~$127.1 million if…
[Business graph, chart green background.Copy space] design master Stock futures edged higher early Tuesday as investors tracked renewed Middle East tensions while eyeing key economic data later this week. Here are some of Tuesday's biggest…
Major earnings expected before the bell on Tuesday include: * Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) * PayPal Holdings (PYPL [https://seekingalpha.com/symbol/PYPL]) * Energy Transfer LP (ET [https://seekingalpha.com/symbol/ET])…
Ocugen Inc. (NASDAQ:OCGN) is one of the best biotech penny stocks to buy in 2026. On April 1, Ocugen completed dosing ahead of schedule in its Phase 2/3 GARDian3 pivotal clinical trial for OCU410ST, a first-in-class modifier gene therapy f…
MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live…
Ocugen OCGN is advancing a late-stage ophthalmology pipeline built around one-time gene therapies for retinal diseases with large unmet needs. Multiple clinical readouts and regulatory milestones expected in 2026 set up a catalyst-heavy ca…
Ocugen OCGN is pushing a modifier gene therapy platform across several retinal diseases where current options are limited, burdensome, or simply absent. The common thread is a "gene-agnostic" concept that aims to help broad patient groups…
Ocugen OCGN is pushing a modifier gene therapy platform across several retinal diseases where current options are limited, burdensome, or simply absent. The common thread is a “gene-agnostic” concept that aims to help broad patient groups…
It has been about a month since the last earnings report for Ocugen (OCGN). Shares have added about 2.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is…
Ocugen OCGN announced that enrollment and dosing have been completed in the phase II/III GARDian3 pivotal confirmatory study evaluating its pipeline candidate, OCU410ST, for the treatment of Stargardt disease. The milestone was achieved in…
Mirum Pharmaceuticals, Inc. (MIRM) shares soared 5.1% in the last trading session to close at $92.38. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.4% loss…
Ocugen Inc. (NASDAQ:OCGN) is one of the popular penny stocks on Robinhood to buy. On March 2, Ocugen, Inc. (NASDAQ:OCGN) announced the completion of patient enrollment for its Phase 3 liMeliGhT clinical trial. The trial is for evaluating O…